Dr. Reddy’s Laboratories (DRL), its fully owned step-down subsidiary Aurigene Pharmaceutical Services, not-for-profit R&D organisation Drugs for Neglected Diseases initiative and DNDi India Foundation have signed an MoU to develop improved drugs for the treatment of identified neglected tropical diseases (NTDs).

Dr. Reddy’s Laboratories’ API and Services CEO Deepak Sapra has said that DRL is grateful for this opportunity and aims to leverage the parties’ strengths and capabilities to develop new drugs with the idea of making them available in India and countries with high disease burden in these NTDs. “

He further said that this potential partnership reinforces the company’s objective to triple its existing reach to touch over 1.5 billion patients worldwide by 2030.

Neglected tropical diseases (NTDs) refer to a diverse group of tropical infections prevalent in low-income populations in developing regions of Asia, Africa and the Americas. Caused by various pathogens, including viruses and bacteria, NTDs affect 1.7 billion people globally.

Neglected tropical diseases (NTDs) include diseases such as myeloma, leishmaniasis (kala azar), sleeping sickness, scabies, Buruli ulcer, chagas disease, and river blindness.